Summary
Researchers evaluated the safety and tolerability of prolonged use of Ashwagandha (Withania somnifera) after vaccination with COVISHIELD™ in a multicenter, randomized, double-blind study. Over 24 weeks, participants who received Ashwagandha showed a stable immune response and no significant side effects. The study, led by Arvind Chopra and colleagues, suggests that the herb may be a safe option for immune support in vaccinated individuals. Although the results are promising, it is important to consider that the research was conducted in a controlled setting and that more studies are needed to confirm these findings in broader populations.
Key points
- Ashwagandha demonstrated safety in prolonged use after vaccination with COVISHIELD™.
- The study was randomized and double-blind, increasing the validity of the results.
- No significant side effects were reported during the 24 weeks of follow-up.
- The research suggests a potential immune support of Ashwagandha after vaccination.
- Limitations include the need for more studies in diverse populations.
✦ For you
If you received the COVISHIELD™ vaccine and are interested in immune support, consider observing how you feel when incorporating Ashwagandha into your routine. Pay attention to any changes in your energy or overall well-being. If you have doubts or persistent symptoms, seek a qualified healthcare professional.
For practitionersExpand
Consider including Ashwagandha (Withania somnifera) in immune support protocols for patients who received the COVISHIELD™ vaccine, especially in cases of post-vaccination fatigue or stress. Evaluate patients' responses over time and adjust the formulation as needed, always respecting each individual's uniqueness.